SCHEMBL2552028

SCHEMBL2552028

Nc1ccc(Sc2ccnc(Cl)c2)c2ccccc12

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NCF1 P14598 1/20 0.38
NR4A2 P43354 5/20 0.37
ALDH1A1 P00352 3/20 0.36
KDM4E B2RXH2 2/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
THRB P10828 1/20 0.36
ADORA2A P29274 1/20 0.36
ADORA1 P30542 1/20 0.36
MEN1 O00255 1/20 0.35
HPGD P15428 1/20 0.35
KMT2A Q03164 1/20 0.35
GRM5 P41594 1/20 0.35
SOS2 Q07890 1/20 0.34
TRPA1 O75762 1/20 0.34
PKM P14618 1/20 0.34
MMP14 P50281 1/20 0.34
MAPK14 Q16539 1/20 0.33
LOX P28300 1/20 0.33
LOXL3 P58215 1/20 0.33
LOXL2 Q9Y4K0 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2555403 0.85 NCF1 (0.40) NCF1NR4A2ALDH1A1KDM4ESMN1; SMN2
SCHEMBL190818 0.79 SIRT2 (0.44) NCF1ALDH1A1SMN1; SMN2ADORA2AADORA1
SCHEMBL2552183 0.77 PDE7A (0.47) ALDH1A1KDM4ESMN1; SMN2MEN1KMT2A
SCHEMBL191204 0.74 HPGD (0.44) ALDH1A1KDM4EHPGDKMT2AGRM5
SCHEMBL11716017 0.73 TUBB4A (0.44) ALDH1A1KDM4EADORA2AMEN1HPGD
SCHEMBL191141 0.72 TRPA1 (0.47) ALDH1A1KDM4ESMN1; SMN2ADORA2AADORA1
SCHEMBL191123 0.72 AR (0.41) ALDH1A1HPGDGRM5TRPA1MAPK14
SCHEMBL1460674 0.69 MAPT (0.54) ALDH1A1KDM4ESMN1; SMN2ADORA2AADORA1
SCHEMBL191746 0.69 ALDH1A1 (0.40) ALDH1A1HPGDGRM5TRPA1
SCHEMBL192450 0.69 AR (0.39) GRM5TRPA1MAPK14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2556068-B1 P38 MAP KINASE INHIBITORS RESPIVERT LTD (GB) 2019-01-23 EP disclosed
US-9024041-B2 P38 MAP kinase inhibitors RESPIVERT LTD. (GB) 2015-05-05 US disclosed
US-20130040962-A1 P38 MAP Kinase Inhibitors RESPIVERT LTD (GB) 2013-02-14 US disclosed
EP-2556068-A1 P38 MAP KINASE INHIBITORS Respivert Limited (GB) 2013-02-13 EP disclosed
WO-2011124930-A1 P38 MAP KINASE INHIBITORS RESPIVERT LIMITED (GB) 2011-10-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130040962-A1 P38 MAP Kinase Inhibitors MAPK15, MAPK1, MAP3K15 NCF1 906/4885NR4A2 2510/4885ALDH1A1 1479/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.